

## APC/Cyanine7 anti-mouse F4/80 Antibody

<b>Catalog# / Size</b>	123117 / 25 µg 123118 / 100 µg
<b>Clone</b>	BM8
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	EMR1, Ly71
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	F4/80 is a 160 kD glycoprotein. It is characterized as a member of the epidermal growth factor (EGF)-transmembrane 7 (TM7) family. F4/80, also known as EMR1 or Ly71, has been widely used as a murine macrophage marker, which is expressed on the majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen (but not on the macrophages located in T cell areas of the spleen, lymph node and Peyer's patch), Kuffer cells, Langerhans cells, and bone marrow stromal cells. F4/80 has also been shown on a subset of dendritic cells. The biological ligand of F4/80 has not been identified, but it has been reported that F4/80 is required for induction of CD8 <sup>+</sup> T cells-mediated peripheral tolerance.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Murine macrophages
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is = 1.0 µg per 10 <sup>6</sup> cells in 100 µl. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections <sup>1,2</sup> and formalin-fixed paraffin-embedded sections <sup>6,7</sup> , Western blotting, and spatial biology (IBEX) <sup>12,13</sup> .
<b>Additional Product Notes</b>	BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact <a href="#">Technical Service</a> if you have any questions.
<b>Application References</b>	<ol style="list-style-type: none"> <li>Schaller E, <i>et al.</i> 2002. <i>Mol. Cell. Biol.</i> 22:8035. (IHC)</li> <li>Stevceva L, <i>et al.</i> 2001. <i>BMC Clin Pathol.</i> 1:3. (IHC)</li> <li>Kobayashi M, <i>et al.</i> 2008. <i>J. Leukoc. Biol.</i> 83:1354. <a href="#">PubMed</a></li> <li>Poeckel D, <i>et al.</i> 2009. <i>J. Biol Chem.</i> 284:21077. <a href="#">PubMed</a></li> <li>Glass AM, <i>et al.</i> 2013. <i>J. Immunol.</i> 190:4830. <a href="#">PubMed</a></li> <li>Koehn S, <i>et al.</i> 2007. <i>J. Allergy Clin. Immunol.</i> 120:570. (IHC)</li> <li>Rankin AL, <i>et al.</i> 2010. <i>J. Immunol.</i> 184:1526. (IHC)</li> <li>Sasi SP, <i>et al.</i> 2014. <i>J Biol Chem.</i> 289:14178. <a href="#">PubMed</a></li> </ol>

9. Thakus VS, *et al.* 2014. *Toxicol Lett.* 230:322. [PubMed](#)
10. Watson NB, *et al.* 2015. *J Immunol.* 194:2796. [PubMed](#)
11. Hirakawa H, *et al.* 2015. *PLoS One.* 10:119360. [PubMed](#)
12. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
13. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Bruand M, *et al.* 2021. *Cell Reports.* 36(3):109412. [PubMed](#)
2. Grandjean CL, *et al.* 2021. *Sci Adv.* 7:. [PubMed](#)
3. Ferrere G, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
4. Resende M, *et al.* 2017. *J Immunol.* 10.4049/jimmunol.1601701. [PubMed](#)
5. Farsakoglu Y *et al.* 2019. *Cell reports.* 26(9):2307-2315 . [PubMed](#)
6. Pilch Z, *et al.* 2018. *Cancer Immunol Res.* 6:930. [PubMed](#)
7. Marques RM, *et al.* 2021. *Cell Death Differ.* 28:3140. [PubMed](#)
8. Coleby R, *et al.* 2021. *Clin Exp Rheumatol.* :39. [PubMed](#)
9. Zhang S, *et al.* 2021. *Cell.* 184(8):2151-2166.e16. [PubMed](#)
10. Vicario N, *et al.* 2021. *Cell Death Disease.* 12(7):625. [PubMed](#)
11. Culina S, *et al.* 2014. *PLoS One.* 9:88365. [PubMed](#)
12. Kozijn AE, *et al.* 2019. *Osteoarthritis Cartilage.* 27:118. [PubMed](#)
13. Zhao J, *et al.* 2019. *Nat Commun.* 10:899. [PubMed](#)
14. Diao L, *et al.* 2022. *iScience.* 25:105511. [PubMed](#)
15. Nawaz A, *et al.* 2022. *Nat Commun.* 13:7058. [PubMed](#)
16. Andreas N, *et al.* 2021. *Arthritis Res Ther.* 23:222. [PubMed](#)
17. Rybalko V, *et al.* 2015. *PLoS One.* 10: 0145550. [PubMed](#)
18. Ohtsuki T, *et al.* 2016. *J Virol.* 90: 300 - 307. [PubMed](#)
19. Ushio A, *et al.* 2017. *Int J Mol Sci.* 10.3390/ijms18061209. [PubMed](#)
20. Wang X, *et al.* 2020. *Signal Transduct Target Ther.* 5:35. [PubMed](#)
21. Bode K, *et al.* 2020. *Cell Reports.* 29(13):4435-4446.e9.. [PubMed](#)
22. Nguyen SL, *et al.* 2021. *Sci Rep.* 11:4217. [PubMed](#)
23. Li S, *et al.* 2021. *Ann Transl Med.* 9:1644. [PubMed](#)
24. Dias AMM, *et al.* 2021. *J Gastroenterol.* 56:442. [PubMed](#)
25. Chen C, *et al.* 2017. *Cell Rep.* 10.1016/j.celrep.2017.02.040. [PubMed](#)
26. Herbst S, *et al.* 2013. *Dis Model Mech.* 6:643. [PubMed](#)
27. Wang Y, *et al.* 2022. *Front Immunol.* 13:767630. [PubMed](#)
28. Han YH, *et al.* 2021. *Science.* 373:. [PubMed](#)
29. Forni MF, *et al.* 2021. *Front Oncol.* 11:667715. [PubMed](#)
30. Ohta S, *et al.* 2013. *J Immunol.* 190:5927. [PubMed](#)
31. Mason K, *et al.* 2013. *J Immunol.* 191:2457. [PubMed](#)
32. Levine LS, *et al.* 2021. *Immunity.* 54(4):829-844.e5. [PubMed](#)
33. Li J, *et al.* 2020. *Cancer Discov.* . [PubMed](#)
34. Zhang D, *et al.* 2020. *Signal Transduct Target Ther.* 5:24. [PubMed](#)
35. Brykczynska U, *et al.* 2020. *Cell Reports.* 30(5):1627-1643.e7.. [PubMed](#)
36. Li J, *et al.* 2020. *Cancer Immunol Res.* 0.529166667. [PubMed](#)
37. Taguchi K, *et al.* 2015. *J Urol.* . [PubMed](#)
38. Benechet AP, *et al.* 2019. *Nature.* 574:200. [PubMed](#)
39. Domingos-Pereira S, *et al.* 2019. *Cancer Immunol Res.* 7:621. [PubMed](#)
40. Adams NM *et al.* 2018. *Immunity.* 48(6):1172-1182 . [PubMed](#)
41. Haase C, *et al.* 2022. *Nat Methods.* 19:1622. [PubMed](#)
42. Peruzzotti-Jametti L, *et al.* 2021. *PLoS Biol.* 19:e3001166. [PubMed](#)
43. Taguchi K, *et al.* 2014. *J Am Soc Nephrol.* 25:1680. [PubMed](#)
44. Wiedemann GM, *et al.* 2020. *Cell Rep.* 33:108498. [PubMed](#)
45. Li J, *et al.* 2018. *Immunity.* 49:178. [PubMed](#)
46. Diaz-Salazar C, *et al.* 2020. *Cell Rep.* 32:108186. [PubMed](#)
47. Gao S, *et al.* 2022. *Cell Res.* 32:38. [PubMed](#)
48. Bayik D, *et al.* 2020. *Cancer Discov.* 1.256944444. [PubMed](#)
49. Xue N, *et al.* 2017. *Sci Rep.* 7:39011. [PubMed](#)
50. Watanabe E, *et al.* 2020. *Angiogenesis.* 23(4):667-684. [PubMed](#)
51. Haloul M, *et al.* 2019. *Sci Rep.* 9:14050. [PubMed](#)
52. Guo M, *et al.* 2018. *J Immunol.* 200:1039. [PubMed](#)
53. Habib S, *et al.* 2018. *Infect Immun.* 86:e00019. [PubMed](#)
54. Yang M, *et al.* 2021. *Cancer Immunol Immunother.* 70:2467. [PubMed](#)
55. Sharma A, *et al.* 2020. *Cell.* 183(2):377-394.e21. [PubMed](#)
56. De Simone G, *et al.* 2021. *Immunity.* . [PubMed](#)
57. Pilch Z, *et al.* 2019. *PLoS One.* 14:e0210796. [PubMed](#)
58. Sasaki T, *et al.* 2020. *Cell Reports.* 28(1):202-217.e7.. [PubMed](#)
59. Liang J, *et al.* 2020. *Sci Adv.* 6:eabc3646. [PubMed](#)
60. Bugler-Lamb AR, *et al.* 2021. *Mol Metab.* 49:101197. [PubMed](#)
61. Grioni M, *et al.* 2021. *Blood Adv.* 5:2817. [PubMed](#)
62. Bourque J, *et al.* 2021. *Heliyon.* 7:e08311. [PubMed](#)
63. Shen M, *et al.* 2022. *Nat Cancer.* 3:60. [PubMed](#)
64. Briot C, *et al.* 2021. *Immunity.* . [PubMed](#)
65. Ni J, *et al.* 2020. *Immunity.* 52(6):1075-1087.e8. [PubMed](#)
66. Zordan P, *et al.* 2013. *Eur J Pharmacol.* 715:296. [PubMed](#)
67. Georgoudaki A, *et al.* 2016. *Cell Rep.* 15: 2000-2011. [PubMed](#)
68. Carestia A, *et al.* 2019. *Cell Rep.* 28:896. [PubMed](#)
69. Lebel MÈ, *et al.* 2020. *Nat Commun.* 3.051388889. [PubMed](#)
70. Kolodkin-Gal D, *et al.* 2021. *Gut.* Online ahead of print. [PubMed](#)
71. Taddio MF, *et al.* 2021. *Mol Imaging Biol.* 23:196. [PubMed](#)
72. Nuro-Gyina PK, *et al.* 2021. *J Immunol.* 207:868. [PubMed](#)

73. Bagadia P, *et al.* 2019. *Nat Immunol.* 20:1174. [PubMed](#)
74. Takahashi F, *et al.* 2022. *iScience.* 25:104278. [PubMed](#)
75. Moro T, *et al.* 2016. *PLoS One.* 11: 0146592. [PubMed](#)
76. Dichtl S, *et al.* 2022. *Life Sci Alliance.* 5:. [PubMed](#)
77. Bergquist M, *et al.* 2014. *J Infect.* 69:113. [PubMed](#)
78. Natale CA, *et al.* 2018. *Elife.* 7. [PubMed](#)
79. Zhu K, *et al.* 2022. *EMBO Rep.* 23:e54499. [PubMed](#)
80. Xu JL, *et al.* 2022. *Front Pharmacol.* 13:911663. [PubMed](#)
81. de Assis LVM, *et al.* 2022. *Commun Biol.* 5:461. [PubMed](#)
82. Zhang W, *et al.* 2021. *Front Immunol.* 12:768435. [PubMed](#)
83. Ni Y, *et al.* 2021. *Theranostics.* 11:9431. [PubMed](#)
84. Casselli T, *et al.* 2021. *PLoS Pathog.* 17:e1009256. [PubMed](#)
85. Klose R, *et al.* 2016. *Nat Commun.* 7:12528. [PubMed](#)
86. Zhang D, *et al.* 2020. *Signal Transduct Target Ther.* 5:24. [PubMed](#)
87. Peruzzotti-Jametti L, *et al.* 2018. *Cell Stem Cell.* 22:355. [PubMed](#)
88. Leiria LO *et al.* 2019. *Cell Metab.* 30(4):768-783 . [PubMed](#)
89. Yoshida H, *et al.* 2019. *Cell.* 176:897. [PubMed](#)
90. Fedele C, *et al.* 2021. *J Exp Med.* 218: . [PubMed](#)
91. Zhang Z, *et al.* 2020. *Front Immunol.* 11:583276. [PubMed](#)
92. Smith KJ, *et al.* 2022. *PLoS Biol.* 20:e3001554. [PubMed](#)
93. Deliyannis G, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
94. Wang M, *et al.* 2021. *iScience.* 24(7):102766. [PubMed](#)
95. Kwok I, *et al.* 2020. *Immunity.* 53(2):303-318.e5. [PubMed](#)
96. DeFalco T, *et al.* 2016. *Cell Rep.* 12: 1107-1119. [PubMed](#)
97. Bertuzzi M, *et al.* 2014. *PLoS Pathog.* 10:1004413. [PubMed](#)
98. Celià-Terrassa T, *et al.* 2017. *Nat Cell Biol.* 19:711. [PubMed](#)
99. Geary CD *et al.* 2018. *Cell reports.* 24(8):1949-1957 . [PubMed](#)
100. Herbst S, *et al.* 2015. *EMBO Mol Med.* 30:240. [PubMed](#)
101. Cardoso M, *et al.* 2015. *Infect Immun.* 83: 3534-3544. [PubMed](#)
102. Chen Z, *et al.* 2016. *Innate Immunity.* 22: 419 - 432. [PubMed](#)
103. Kahn JH, *et al.* 2020. *Endocrinology.* 161(10):. [PubMed](#)
104. Mellal K, *et al.* 2019. *Sci Rep.* 9:12903. [PubMed](#)
105. Sameshima A, *et al.* 2015. *J Endocrinol.* 227: 25-36. [PubMed](#)
106. Morrissey MA, *et al.* 2018. *Elife.* 7:e36688. [PubMed](#)
107. Yáñez A *et al.* 2017. *Immunity.* 47(5):890-902 . [PubMed](#)
108. Patterson DG, *et al.* 2021. *J Immunol.* 207:1798. [PubMed](#)
109. Andreato F, *et al.* 2021. *STAR Protoc.* 2:100831. [PubMed](#)
110. Ren X, *et al.* 2021. *Cell Death Dis.* 12:484. [PubMed](#)

**RRID** AB\_893489 (BioLegend Cat. No. 123117)  
 AB\_893477 (BioLegend Cat. No. 123118)

## Antigen Details

---

<b>Structure</b>	EGF-TM7 family member, 160 kD glycoprotein
<b>Distribution</b>	Majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen, Kuffer cells, Langerhans cells, bone marrow stromal cells, and a subset of dendritic cells
<b>Function</b>	Induction of immunological tolerance
<b>Cell Type</b>	Dendritic cells, Langerhans cells, Macrophages, Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Austy JM and Gordon S. 1981. <i>Eur. J. Immunol.</i> 11:805.</li> <li>2. Hume DA, <i>et al.</i> 1983. <i>J. Exp. Med.</i> 158:1522.</li> <li>3. Ruedl C, <i>et al.</i> 1996. <i>Eur. J. Immunol.</i> 26:1801.</li> <li>4. McKnight AJ, <i>et al.</i> 1996. <i>J. Biol. Chem.</i> 271:486.</li> <li>5. Lin HH, <i>et al.</i> 2005. <i>J. Exp. Med.</i> 201:1615.</li> </ol>
<b>Gene ID</b>	<a href="#">13733</a>

## Related Protocols


---

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

Brilliant Violet 605™ anti-mouse F4/80, Purified anti-mouse F4/80, Biotin anti-mouse F4/80, FITC anti-mouse F4/80, PE anti-mouse F4/80, PE/Cyanine5 anti-mouse F4/80, PE/Cyanine7 anti-mouse F4/80, APC anti-mouse F4/80, APC/Cyanine7 anti-mouse F4/80, Alexa Fluor® 488 anti-mouse F4/80, Alexa Fluor® 647 anti-mouse F4/80, Pacific Blue™ anti-mouse F4/80, PerCP anti-mouse F4/80, PerCP/Cyanine5.5 anti-mouse F4/80, Alexa Fluor® 700 anti-mouse F4/80, Brilliant Violet 421™ anti-mouse F4/80, Brilliant Violet 510™ anti-mouse F4/80, Alexa Fluor® 594 anti-mouse F4/80, Brilliant Violet 785™ anti-mouse F4/80, Purified anti-mouse F4/80 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse F4/80, Brilliant Violet 650™ anti-mouse F4/80, Brilliant Violet 711™ anti-mouse F4/80, APC/Fire™ 750 anti-mouse F4/80, TotalSeq™-A0114 anti-mouse F4/80, TotalSeq™-B0114 anti-mouse F4/80, TotalSeq™-C0114 anti-mouse F4/80, Spark YG™ 570 anti-mouse F4/80, KIRAVIA Blue 520™ anti-mouse F4/80, Ultra-LEAF™ Purified anti-mouse F4/80, APC/Fire™ 810 anti-mouse F4/80, Spark NIR™ 685 anti-mouse F4/80

## Product Data



Thioglycolate-elicited Balb/c mouse peritoneal macrophages were stained with CD11b FITC and F4/80 (clone BM8) APC/Cyanine7 (left) or Rat IgG2a, κ APC/Cyanine7 isotype control (right).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587